• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Zasocitinib’s Phase 3 Success in Hard-to-Treat Psoriasis Areas Change The Bull Case For Takeda Pharmaceutical (TSE:4502)?

    Simply Wall St·07/17/2026 06:27:45
    Listen to the news
    • In July 2026, Takeda reported positive Phase 3 results for its oral TYK2 inhibitor zasocitinib in adults with moderate-to-severe plaque psoriasis, showing rapid, durable skin clearance even in hard-to-treat areas such as the scalp, nails, palms and soles versus placebo.
    • By highlighting strong efficacy in high-impact, difficult-to-treat sites, the zasocitinib data point to a potentially differentiated psoriasis therapy within Takeda’s immunology pipeline.
    • We’ll now examine how zasocitinib’s late-stage success in hard-to-treat plaque psoriasis areas may influence Takeda’s existing investment narrative.

    We've uncovered the 43 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    Takeda Pharmaceutical Investment Narrative Recap

    To own Takeda today, you have to believe its late stage pipeline can gradually rebalance the story away from patent expiries and high debt. The zasocitinib Phase 3 psoriasis data strengthen the case that immunology could be a meaningful growth driver, but they do not change the near term focus: how quickly new launches can offset VYVANSE erosion and whether rising R&D and launch costs pressure margins.

    Among recent announcements, the Indonesia plasma ecosystem collaboration stands out alongside zasocitinib. While unrelated scientifically, both speak to Takeda’s push to build durable, higher value franchises beyond legacy blockbusters, with plasma derived therapies and immunology sitting next to narcolepsy and PV as key potential contributors to future earnings.

    Yet investors should also weigh how quickly pipeline assets like zasocitinib must ramp to counter pricing reform and biosimilar pressure on existing high margin drugs that investors should be aware of...

    Read the full narrative on Takeda Pharmaceutical (it's free!)

    Takeda Pharmaceutical's narrative projects ¥4,805.7 billion revenue and ¥355.8 billion earnings by 2029. This requires 2.2% yearly revenue growth and about a ¥164.0 billion earnings increase from ¥191.8 billion today.

    Uncover how Takeda Pharmaceutical's forecasts yield a ¥6137 fair value, a 15% upside to its current price.

    Exploring Other Perspectives

    TSE:4502 1-Year Stock Price Chart
    TSE:4502 1-Year Stock Price Chart

    The most optimistic analysts already expected revenue near ¥5,072.4 billion and earnings around ¥423.0 billion by 2029, so zasocitinib’s strong data may either reinforce that bullish view or highlight how much has to go right, reminding you that reasonable people can read the same numbers very differently.

    Explore 2 other fair value estimates on Takeda Pharmaceutical - why the stock might be worth over 3x more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Looking For Alternative Opportunities?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.